Health ❯ Obesity ❯ Weight Loss

Medications

GLP-1 Receptor Agonists GLP-1 Drugs Mounjaro Semaglutide Wegovy GLP-1 Agonists Ozempic Tirzepatide GLP-1 Zepbound NHS Long-term Effects GLP-1 Therapies GLP-1 Injections Long-term Use GLP-1s Copycat Drugs Orforglipron Eli Lilly Semaglutide and Tirzepatide Mounjaro and Wegovy Wegovy and Mounjaro GLP-1 Treatments Weight Loss Medicines Novo Nordisk Subsidization GLP-1 Medications Side Effects Hormonal Treatments Ozempic and Wegovy NHS Services Medicare and Medicaid Coverage Wegovy and Ozempic Semaglutides GLP-1RA Benefits Public Opinion Long-term Treatment Diabetes Treatment Drug Efficacy Clinical Trials

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

UBT251 targets GLP‑1, GIP plus glucagon for a mechanistically distinct approach to weight management.

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Pilot Study Ties GLP-1 Drugs to Slower Alcohol Absorption and Milder Intoxication

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

GLP-1 Weight-Loss Drugs Linked to Testosterone Normalization in Men

GLP-1 Drugs Linked to Lower Cancer Risk and Mortality in New Study